Related Experiment Videos
Management of progressive metastatic prostate cancer
1Hematology-Oncology Service, Walter Reed Army Medical Center, Washington, DC, USA.
Abstract:
Metastatic prostate cancer is a growing health problem and is the second leading cause of cancer death in men. While the response of patients with metastatic prostate cancer to initial hormonal manipulation is excellent, the majority of patients eventually progress. As a result, a growing number of patients and their physicians need-to-find acceptable therapeutic alternatives. Fortunately, the number of therapies in the management armamentarium is growing and includes: alternative hormonal therapies, chemotherapy, radioisotopes, and investigational agents. The major focus of treatment has shifted to palliation and quality of life. The decline of prostate-specific antigen (PSA) has become another important end point as evidence supporting a correlation with prolonged survival mounts. Enrolling eligible patients in clinical trials is critical to the development of new treatment strategies for this difficult disease.
Insights
Metastatic prostate cancer requires new treatments as patients often progress after initial hormonal therapy. Research is expanding therapeutic options, focusing on quality of life and clinical trials for advanced prostate cancer.
Area of Science:
- Oncology
- Urology
Background:
- Metastatic prostate cancer is a significant health concern and a leading cause of cancer death in men.
- Initial hormonal therapy is effective, but most patients eventually experience disease progression.
Purpose of the Study:
- To review current and emerging therapeutic alternatives for metastatic prostate cancer.
- To highlight the shift in treatment focus towards palliation and quality of life.
Main Methods:
- Literature review of current treatment strategies for metastatic prostate cancer.
- Discussion of emerging therapies including hormonal agents, chemotherapy, radioisotopes, and investigational drugs.
Main Results:
- The number of therapeutic options for metastatic prostate cancer is increasing.
- Prostate-specific antigen (PSA) decline is an important endpoint, correlating with survival.
Conclusions:
- Managing advanced prostate cancer involves exploring diverse treatment options beyond initial hormonal manipulation.
- Clinical trial enrollment is crucial for advancing treatment strategies and improving outcomes for patients with metastatic prostate cancer.